Medicinal Composition for Treating Intractable Heart Disease

Patent metadata

Field	Value
Publication number	US-2020360391-A1
Application number	US-202015929975-A
Country	US
Kind code	A1
Filing date	Jun 1, 2020
Priority date	Dec 27, 2016
Publication date	Nov 19, 2020
Grant date	—

Abstract

The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.)

First claim

1 - 15 . (canceled)

16 . A method of pharmaceutical composition for use in preventing and/or treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure in a subject indeed thereof, comprising administering an effective amount of a pharmaceutical composition to the subject.

17 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises a protease inhibitor.

18 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises a thromboxane A 2 synthase inhibitor and/or a thromboxane A 2 synthase antagonist.

19 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises a phosphodiesterase (PDE) inhibitor.

20 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises a tyrosine kinase inhibitor.

21 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises an HMG-CoA reductase inhibitor.

22 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises an antifibrotic agent.

23 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises at least two members selected from the group consisting of a protease inhibitor, a thromboxane A 2 synthase inhibitor, a thromboxane A 2 synthase antagonist, a phosphodiesterase (PDE) inhibitor, a tyrosine kinase inhibitor, an HMG-CoA reductase inhibitor, and an antifibrotic agent.

24 . The method pharmaceutical composition according to claim 16 , comprising wherein the pharmaceutical composition comprises at least one member selected from the group consisting of the following compounds (1) to (6) and salts thereof:
(1) camostat as a protease inhibitor; (2) ozagrel as a thromboxane A 2 synthase inhibitor; (3) theophylline, cilostazol, and sildenafil as phosphodiesterase inhibitors; (4) nintedanib as a tyrosine kinase inhibitor; (5) lovastatin as an HMG-CoA reductase inhibitor; and (6) pirfenidone as an antifibrotic agent.

25 . The method pharmaceutical composition according to claim 16 , wherein the pharmaceutical composition is a long-acting preparation further comprising a biodegradable polymer.

26 . The method pharmaceutical composition according to claim 25 , wherein the long-acting preparation is a microsphere preparation, a microcapsule preparation, or a nanosphere preparation.

27 . The method pharmaceutical composition according to claim 25 , wherein the biodegradable polymer is a poly(lactic-co-glycolic acid), and the long-acting preparation is a microsphere preparation.

28 . The method pharmaceutical composition according to claim 26 , wherein the pharmaceutical composition comprises at least one member selected from the group consisting of the following compounds (1) to (5) and salts thereof:
(1) camostat as a protease inhibitor; (2) ozagrel as a thromboxane A 2 synthase inhibitor; (3) cilostazol and sildenafil as phosphodiesterase inhibitors; (4) nintedanib as a tyrosine kinase inhibitor; and (5) pirfenidone as an antifibrotic agent.

29 . The method pharmaceutical composition according to claim 16 , wherein the pharmaceutical composition which is administered by for oral administration, intravenous administration, intracoronary administration, inhalation, intramuscular injection, subcutaneous administration, transmucosal administration, transdermal administration, or cardiac patch application.

30 . The method pharmaceutical composition according to claim 16 , wherein the intractable heart tissue fibrosis disease accompanied by chronic heart failure is dilated cardiomyopathy, ischemic cardiomyopathy, myocardial infarction, angina pectoris, arteriosclerosis, vasculitis syndrome, myocarditis, hypertrophic cardiomyopathy, aortic valve stenosis, valvular disease, aortic regurgitation, HFpEF (heart failure with preserved ejection fraction), diastolic dysfunction, contractile dysfunction, supraventricular tachyarrhythmia, congestive heart failure, coronary artery disease, idiopathic cardiomyopathy, or atrial fibrillation.

Assignees

• Univ Osaka
• Cardio Incorporated

Inventors

• Sawa Yoshiki
• Miyagawa Shigeru
• Sakai Yoshiki
• Yanagi Yasuhiro

Classifications

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/5585

  having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin · CPC title

• A61K31/4409

  only substituted in position 4, e.g. isoniazid, iproniazid · CPC title

• A61K31/245

  Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60) · CPC title

• C07D309/30

  Oxygen atoms, e.g. delta-lactones · CPC title